This company has been marked as potentially delisted and may not be actively trading. Anchiano Therapeutics (ANCN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ANCN vs. MRNS, ALLK, CARA, HILS, NNVC, ME, IBIO, GLYC, ORGS, and AEONShould you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include Marinus Pharmaceuticals (MRNS), Allakos (ALLK), Cara Therapeutics (CARA), Hillstream BioPharma (HILS), NanoViricides (NNVC), 23andMe (ME), iBio (IBIO), GlycoMimetics (GLYC), Orgenesis (ORGS), and AEON Biopharma (AEON). These companies are all part of the "medical" sector. Anchiano Therapeutics vs. Its Competitors Marinus Pharmaceuticals Allakos Cara Therapeutics Hillstream BioPharma NanoViricides 23andMe iBio GlycoMimetics Orgenesis AEON Biopharma Anchiano Therapeutics (NASDAQ:ANCN) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability. Is ANCN or MRNS more profitable? Anchiano Therapeutics has a net margin of 0.00% compared to Marinus Pharmaceuticals' net margin of -446.48%. Anchiano Therapeutics' return on equity of 36.08% beat Marinus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Anchiano TherapeuticsN/A 36.08% 27.40% Marinus Pharmaceuticals -446.48%-7,831.35%-120.74% Do analysts rate ANCN or MRNS? Marinus Pharmaceuticals has a consensus target price of $3.92, suggesting a potential upside of 613.29%. Given Marinus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Marinus Pharmaceuticals is more favorable than Anchiano Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anchiano Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Marinus Pharmaceuticals 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40 Do institutionals and insiders believe in ANCN or MRNS? 9.1% of Anchiano Therapeutics shares are held by institutional investors. Comparatively, 98.8% of Marinus Pharmaceuticals shares are held by institutional investors. 6.9% of Anchiano Therapeutics shares are held by company insiders. Comparatively, 5.5% of Marinus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, ANCN or MRNS? Anchiano Therapeutics has higher earnings, but lower revenue than Marinus Pharmaceuticals. Anchiano Therapeutics is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnchiano TherapeuticsN/AN/A-$27.12M-$3.46-0.34Marinus Pharmaceuticals$30.99M0.98-$141.40M-$2.47-0.22 Does the media prefer ANCN or MRNS? In the previous week, Anchiano Therapeutics' average media sentiment score of 0.00 equaled Marinus Pharmaceuticals'average media sentiment score. Company Overall Sentiment Anchiano Therapeutics Neutral Marinus Pharmaceuticals Neutral Which has more risk & volatility, ANCN or MRNS? Anchiano Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. SummaryMarinus Pharmaceuticals beats Anchiano Therapeutics on 8 of the 14 factors compared between the two stocks. Get Anchiano Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANCN vs. The Competition Export to ExcelMetricAnchiano TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.68M$825.13M$5.47B$8.93BDividend YieldN/A4.84%5.34%4.14%P/E Ratio7.801.1126.1419.65Price / SalesN/A222.96387.56105.07Price / CashN/A23.4436.4056.84Price / Book0.586.117.875.43Net Income-$27.12M-$26.95M$3.16B$249.20M Anchiano Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANCNAnchiano TherapeuticsN/A$1.17-2.0%N/A+28.2%$8.68MN/A7.8016Gap UpMRNSMarinus Pharmaceuticals2.2418 of 5 stars$0.55-0.2%$3.92+613.3%-53.1%$30.32M$30.99M-0.22110ALLKAllakos2.7838 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190CARACara Therapeutics0.305 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeHILSHillstream BioPharmaN/A$1.34-6.3%N/A-44.2%$23.59MN/A-1.861NNVCNanoViricides0.3943 of 5 stars$1.40+2.2%N/A-18.4%$22.50MN/A-1.9420Gap UpME23andMeN/A$0.50-35.3%N/A-93.6%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeIBIOiBio1.6019 of 5 stars$0.75+5.4%$4.30+474.9%-64.0%$12.36M$375K0.00100Analyst ForecastGap DownHigh Trading VolumeGLYCGlycoMimetics1.802 of 5 stars$0.16-6.6%N/A-99.4%$10.00M$10K-0.3450High Trading VolumeORGSOrgenesis1.7772 of 5 stars$1.75+0.3%N/AN/A$8.40M$662K0.00150Gap UpAEONAEON Biopharma3.5829 of 5 stars$0.71+0.1%$360.00+50,747.5%-98.9%$8.00MN/A3.935Positive News Related Companies and Tools Related Companies MRNS Alternatives ALLK Alternatives CARA Alternatives HILS Alternatives NNVC Alternatives ME Alternatives IBIO Alternatives GLYC Alternatives ORGS Alternatives AEON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANCN) was last updated on 6/29/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anchiano Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anchiano Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
